The adjusted EPS beat and raised guidance are positive, but organic growth of 1.3% and GAAP losses temper enthusiasm. Watch Q2 revenue guidance ($410M-$425M, implying potential YoY decline) and the Braintree facility timeline for SurgiMend launch — execution on manufacturing ramp is key to sustaining momentum. The CEO transition adds uncertainty; monitor for any strategic shifts.
Price Chart
Executive Summary
Integra LifeSciences reported Q1 2026 adjusted EPS of $0.54, beating the $0.40 consensus by 35%, on revenue of $391.9M (2.4% YoY growth, slightly above the $381.8M estimate). The company raised its full-year adjusted EPS guidance to $2.40-$2.50 from $2.30-$2.40, citing first-quarter tariff benefits, while reaffirming revenue guidance of $1.662B-$1.702B. Despite the headline beat, GAAP net loss persisted at $(4.6)M, organic revenue growth was a tepid 1.3%, and the stock's small market cap ($830M) and mixed analyst sentiment (13% bullish) suggest limited upside conviction.
Key Financial Metrics
Key Facts
- Adjusted EPS $0.54 vs consensus $0.40 (beat by 35%)
- Revenue $391.9M vs consensus $381.8M (beat by 2.6%)
- GAAP net loss $(4.6)M vs $(25.3)M in prior year
- Full-year adjusted EPS guidance raised to $2.40-$2.50 from $2.30-$2.40
- Full-year revenue guidance reaffirmed at $1.662B-$1.702B (1.6%-4.1% reported growth)
- Organic revenue growth of only 1.3% in Q1
- Adjusted gross margin improved to 64.1% from 62.2%
- Cash flow from operations $9.8M; net debt $1.6B (leverage ratio 4.1x)
- CEO transition announced: Stuart Essig appointed President and CEO
Financial Impact
Adjusted EPS beat by $0.14 (35%) and revenue beat by ~$10M (2.6%); full-year EPS guidance raised by $0.10 at midpoint
Risk Factors
- Organic revenue growth of only 1.3% signals weak underlying demand
- GAAP net loss persists despite adjusted profitability
- High leverage (net debt $1.6B, 4.1x) limits financial flexibility
- Q2 revenue guidance implies potential YoY decline of up to 1.3%
- CEO transition may cause near-term strategic uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287428 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $11.84 | awaiting T+5 | — | $12.13 (−2.41%) |
Oct 19, 2026 6d ago | 8-K | $13.33 | awaiting T+5 | — | $12.13 (−9.04%) |
Oct 14, 2026 12d ago | Court Ruling | $13.53 $12.33 | ▼ −8.91% | ▼ −7.89% | $12.13 (−10.38%) |
Oct 13, 2026 12d ago | 3 | $13.18 $11.84 | ▼ −10.13% | ▼ −10.59% | $12.13 (−7.97%) |
Oct 9, 2026 16d ago | 8-K | $13.98 $13.45 | ▲ +3.79% | ▲ +2.30% | $12.13 (+13.27%) |
Oct 6, 2026 20d ago | Press Release | $13.32 | awaiting T+5 | — | $12.13 (−8.97%) |
Oct 2, 2026 24d ago | 8-K | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.13 (+4.38%) |
Oct 2, 2026 24d ago | Press Release | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.13 (+4.38%) |
Sep 8, 2026 6w ago | 8-K | $16.26 $15.71 | ▼ −3.38% | ▼ −2.72% | $12.13 (−25.43%) |
May 8, 2026 24w ago | 8-K | $13.97 $14.11 | ▲ +1.00% | ▲ +1.09% | $12.13 (−13.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers